517 related articles for article (PubMed ID: 9465685)
21. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
22. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
24. Prevention of cytomegalovirus disease.
Bailey TC
Semin Respir Infect; 1993 Sep; 8(3):225-32. PubMed ID: 8016483
[TBL] [Abstract][Full Text] [Related]
25. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
27. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
[TBL] [Abstract][Full Text] [Related]
28. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
29. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
30. Prevention and treatment of cytomegalovirus infection in organ transplant recipients.
Kusne S; Shapiro R; Fung J
Transpl Infect Dis; 1999 Sep; 1(3):187-203. PubMed ID: 11428989
[TBL] [Abstract][Full Text] [Related]
31. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
32. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
Kowalsky S; Arnon R; Posada R
Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
[TBL] [Abstract][Full Text] [Related]
33. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
[TBL] [Abstract][Full Text] [Related]
34. [Gastrointestinal cytomegalovirus infections in organ transplant patients].
Péter A; Telkes G; Varga M; Járay J
Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914
[TBL] [Abstract][Full Text] [Related]
35. [Progress in the management of cytomegalovirus(CMV) infection].
Tanaka N; Kimura H; Morishima T
Nihon Rinsho; 1998 Jan; 56(1):167-72. PubMed ID: 9465684
[TBL] [Abstract][Full Text] [Related]
36. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.
Duncan SR; Grgurich WF; Iacono AT; Burckart GJ; Yousem SA; Paradis IL; Williams PA; Johnson BA; Griffith BP
Am J Respir Crit Care Med; 1994 Jul; 150(1):146-52. PubMed ID: 8025741
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
Nafar M; Roshan A; Pour-Reza-Gholi F; Samadian F; Ahmadpoor P; Samavat S; Abbasi MA
Iran J Kidney Dis; 2014 May; 8(3):231-5. PubMed ID: 24878947
[TBL] [Abstract][Full Text] [Related]
38. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
39. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
McGavin JK; Goa KL
Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
[TBL] [Abstract][Full Text] [Related]
40. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
Baillie GM
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]